184 related articles for article (PubMed ID: 7740325)
1. Docetaxel (Taxotere): a highly active taxoid with manageable toxicity.
Aapro MS
Semin Oncol; 1995 Apr; 22(2 Suppl 4):1-2. PubMed ID: 7740325
[No Abstract] [Full Text] [Related]
2. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
3. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
5. The development of docetaxel (Taxotere) in non-small cell lung cancer.
Kris MG; Miller VA; Ng KK; Grant SC
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
[No Abstract] [Full Text] [Related]
6. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) in the treatment of cancer.
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):1-2. PubMed ID: 10810931
[No Abstract] [Full Text] [Related]
8. Nail changes secondary to docetaxel (Taxotere).
Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Verweij J; Clavel M; Chevalier B
Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
[TBL] [Abstract][Full Text] [Related]
10. Taxol and taxotere--current status and future prospects.
Bissett D; Kaye SB
Eur J Cancer; 1993; 29A(9):1228-31. PubMed ID: 8102062
[No Abstract] [Full Text] [Related]
11. Docetaxel (Taxotere): preclinical and general clinical information.
Earhart RH
Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel (taxotere) in the treatment of prostate cancer.
Beer TM; El-Geneidi M; Eilers KM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
[TBL] [Abstract][Full Text] [Related]
13. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
14. [Current developments in use of docetaxel (taxotere) in gynecologic oncology].
Jackisch C
Med Klin (Munich); 1998 Sep; 93 Suppl 3():4-15. PubMed ID: 9796219
[No Abstract] [Full Text] [Related]
15. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Camidge DR; Kunkler IH
Clin Oncol (R Coll Radiol); 2000; 12(4):272-3. PubMed ID: 11005698
[No Abstract] [Full Text] [Related]
17. Treatment of patients resistant to paclitaxel therapy.
Valero V
Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
[TBL] [Abstract][Full Text] [Related]
18. Conclusion: the place of docetaxel (Taxotere) in future therapy.
Khayat D
Anticancer Drugs; 1996 Aug; 7 Suppl 2():53. PubMed ID: 8862713
[No Abstract] [Full Text] [Related]
19. Docetaxel said to be highly effective and well tolerated in advanced head and neck cancer.
Oncology (Williston Park); 1996 Mar; 10(3):422. PubMed ID: 8820455
[No Abstract] [Full Text] [Related]
20. The taxoids: same roots, different drugs.
Von Hoff DD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-3-S13-10. PubMed ID: 9335511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]